Alligator Bioscience


Small Cap


Health Care

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, an immunostimulatory antibody, which is in phase 1 clinical trial for the treatment of metastatic cancer. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; MacroGenics, Inc.; Biotheus Inc.; BioArctic AB; and Abclon Inc. The company was founded in 2000 and is headquartered in Lund, Sweden.



Länk till dynamisk (zoombar) graf för större skärmar

Nuvarande och kommande formation

MA Rank

Rulla till toppen